— Catálogo

Weight Management

The peptides in this category share one field of study: metabolic regulation. They are not a homogeneous group; what brings them together is the research question they address, and understanding how they differ is what lets you pick the right material for a protocol.

Showing 1–12 of 17 results

The pathways under investigation

The largest group is the incretin agonists. Incretins are gut hormones released with food intake, and the compounds in this group differ in how many receptors they activate: Tirzepatide acts on two (GIP and GLP-1), while Retatrutide adds a third axis, the glucagon receptor, which the literature associates with energy expenditure.

Amylin analogs work through a different route. Amylin is co-secreted with insulin and signals satiety through its own receptors in the central nervous system. Cagrilintide represents this line, and CagriReta combines both approaches in a single preparation.

GHRH analogs such as Tesamorelin do not act on satiety but on the growth hormone axis; their literature focuses on visceral adipose tissue. AOD-9604 reproduces only fragment 176-191 of growth hormone, the region linked to lipid metabolism.

Finally, the small molecules, which are not peptides: 5-Amino-1MQ inhibits the NNMT enzyme in adipose tissue, and SLU-PP-332 acts on nuclear receptors involved in oxidative metabolism.

Before you choose

Different presentations of the same compound differ only in vial content; molecule and purity are identical. Higher milligram amounts lower the cost per milligram and suit longer protocols. All material ships lyophilized and requires bacteriostatic water for reconstitution.

Products in this category

All products in this category are intended exclusively for scientific research and laboratory development. They are not medicines, hold no INVIMA sanitary registration and are not fit for human or animal consumption.